Drug Profile
Research programme: prodigiosin-related cancer therapeutics - Aida Pharmaceuticals
Alternative Names: Prodigiosin - Aida PharmaceuticalsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aida Pharmaceuticals
- Class Pyrroles
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pancreatic cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pancreatic-cancer in China